EGFR and breast carcinoma: A total of 64 patients with breast cancer, were identified as having triple-negative breast cancer (17.5%), which 12.6% were basal-like (CK5/6 positive and or Her1 positives), 4.9% were unclassified subtype (CK5/6 and Her1 negatives), a median age and histological tumor diameter were respectively 45 years and 4.3 cm (Table 1).